Spinocerebellar Ataxia Type 10

Spinocerebellar Ataxia Type 10

Overview

Spinocerebellar Ataxia Type 10 is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Spinocerebellar ataxia type 10 (SCA10) is a rare autosomal dominant cerebellar ataxia characterized by progressive cerebellar degeneration and is one of the most common SCAs in Latin American populations[@rasmussen2012][@teive2014].

Epidemiology

• Prevalence: Rare globally (~1 per 100,000), but more common in Latin America (up to 1 per 20,000 in some regions)
• Inheritance: Autosomal dominant
• Age of onset: Typically 15-40 years (mean ~25 years)
• Gender distribution: Equal between males and females
• Geographic distribution: Most common in Mexico, Argentina, Brazil, and Venezuela
• Founder effect: Large kindreds in specific regions trace to common ancestors

Genetics

SCA10 is caused by an expanded ATTCT pentanucleotide repeat in the intron of the ATXN10 gene (chromosome 12q24)[@rasmussen2012][@teive2014].

Gene Details

...

Spinocerebellar Ataxia Type 10

Overview

Spinocerebellar Ataxia Type 10 is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Spinocerebellar ataxia type 10 (SCA10) is a rare autosomal dominant cerebellar ataxia characterized by progressive cerebellar degeneration and is one of the most common SCAs in Latin American populations[@rasmussen2012][@teive2014].

Epidemiology

• Prevalence: Rare globally (~1 per 100,000), but more common in Latin America (up to 1 per 20,000 in some regions)
• Inheritance: Autosomal dominant
• Age of onset: Typically 15-40 years (mean ~25 years)
• Gender distribution: Equal between males and females
• Geographic distribution: Most common in Mexico, Argentina, Brazil, and Venezuela
• Founder effect: Large kindreds in specific regions trace to common ancestors

Genetics

SCA10 is caused by an expanded ATTCT pentanucleotide repeat in the intron of the ATXN10 gene (chromosome 12q24)[@rasmussen2012][@teive2014].

Gene Details

| Feature | Details |
|---------|---------|
| Gene | ATXN10 (Ataxin-10) |
| Chromosome | 12q24.31 |
| Normal repeat | 5-55 ATTCT repeats |
| Pathogenic repeat | 800-4,500 ATTCT repeats |
| Intermediate | 55-850 repeats (reduced penetrance) |
| Protein size | 473 amino acids |
| Subcellular localization | Cytoplasmic, nucleus |
| Tissue expression | Brain (cerebellum), peripheral tissues |
| Normal function | Mitochondrial function, neuronal survival |

Ataxin-10 Normal Function

The wild-type ataxin-10 protein plays important roles in neuronal cells[@rasmussen2012]:

Mitochondrial function: Associates with mitochondria, regulates mitochondrial dynamics

Neuronal survival: Anti-apoptotic functions through PI3K/Akt pathway

RNA metabolism: Binds to specific mRNAs for transport and translation

Tumor suppression: Acts as tumor suppressor in non-neuronal tissues

The loss of these normal functions due to the repeat expansion contributes to neurodegeneration.

Anticipation

• Larger repeats correlate with earlier onset (anticipation)
• Paternal transmission tends to show larger expansions
• Somatic mosaicism has been reported

Pathophysiology

The exact mechanism of neurodegeneration in SCA10 remains under investigation[@rasmussen2012][@teive2014]. SCA10 represents a unique model for understanding pentanucleotide repeat expansion diseases due to its combination of cerebellar degeneration and epilepsy.

Molecular Mechanisms

RNA Toxicity and Repeat Expansion

The expanded ATTCT pentanucleotide repeat forms toxic RNA structures that sequester various RNA-binding proteins[@liu2020]:

Muscleblind-like proteins (MBNL1/2): Sequestration leads to alternative splicing dysregulation

CUG-binding proteins: Disruption of normal RNA processing

hnRNP proteins: Altered mRNA transport and stability

Nuclear factor kappa B (NF-κB): Dysregulated inflammatory responses

This RNA gain-of-function mechanism distinguishes SCA10 from polyglutamine diseases like [Huntington disease](/diseases/huntington-disease) or other SCAs.

Repeat-Associated Non-ATG Translation (RAN Translation)

Unlike traditional translation, RAN translation occurs from the expanded repeat in all three reading frames without requiring an AUG start codon[@zhang2019]:

• Polyglutamine (polyGln): From ATTCT repeats in +2 frame
• Polyalanine (polyAla): From ATTCT repeats in +0 frame
• Polyserine (polySer): From ATTCT repeats in +1 frame

These unconventional peptides are toxic to neurons and may contribute to Purkinje cell death through:

• Protein aggregation
• Oxidative stress
• Mitochondrial dysfunction
• Endoplasmic reticulum stress

Purkinje Cell Degeneration

The cerebellum, particularly [Purkinje cells](/cell-types/purkinje-cells), is the primary target in SCA10[@kuo2023]:

• Cellular pathology: Progressive loss of Purkinje neurons in the cerebellar cortex
• Molecular markers: Reduced calbindin expression, increased GFAP in Bergmann glia
• Circuit dysfunction: Disruption of the cerebellar outflow tracts

Relationship to Other Neurodegenerative Diseases

SCA10 shares molecular mechanisms with several other neurodegenerative conditions:

• Overlap with TDP-43 proteinopathies: Like [ALS](/diseases/amyotrophic-lateral-sclerosis) and [FTD](/diseases/frontotemporal-dementia), SCA10 involves RNA processing dysregulation
• Common pathway with Alzheimer's disease: Both involve protein aggregation and mitochondrial dysfunction
• Seizure mechanism link: Similar to [epilepsy in neurodegenerative diseases](/mechanisms/epilepsy-neurodegeneration), SCA10 shows excitability changes

Clinical Features

Core Symptoms

• Progressive cerebellar ataxia: Gait instability, limb incoordination
• Dysarthria: Slurred speech due to cerebellar dysarthria
• Nystagmus: Horizontal gaze-evoked nystabismus
• Oculomotor abnormalities: Slow saccades, difficulty with smooth pursuit

Associated Features

• Seizures: Epilepsy reported in 10-40% of patients (more common in some families) — a distinguishing feature from most other SCAs
• Cognitive impairment: Mild cognitive deficits in some patients, particularly affecting executive function
• Peripheral neuropathy: Sensory loss in some cases, predominantly small fiber
• Dystonia: Less common than in other SCAs, but can occur
• Cardiac involvement: Rare in SCA10 (distinguishes from Friedreich ataxia)
• Ocular findings: Slow saccades, oculomotor apraxia, nystagmus

Disease Modifiers

Genetic and environmental factors modify disease severity[@teive2014]:

CAG repeat length: In nearby genes may modify age of onset

Modifier genes: Variants in autophagy genes affect progression

Environmental factors: Regular exercise correlates with slower progression

Cognitive reserve: Higher education associated with better outcomes

Disease Course

• Initial symptoms: Gait instability and clumsiness
• Progression: Gradual deterioration over 10-30 years
• Disability: Typically requires wheelchair assistance 10-20 years after onset
• Life expectancy: Generally normal lifespan

Diagnosis

Clinical Assessment

• Detailed neurological examination
• Assessment of ataxia severity (Scale for the Assessment and Rating of Ataxia - SARA)
• Family history (autosomal dominant pattern)

Genetic Testing

• Gold standard: PCR to detect ATTCT repeat expansion in ATXN10 gene
• Confirmatory: Southern blot for precise repeat sizing
• Preymptomatic testing: Available for at-risk family members

Neuroimaging

• MRI: Shows isolated cerebellar atrophy, particularly of the vermis
• Characteristic finding: Predominant atrophy of the cerebellar hemispheres and vermis
• No brainstem involvement: Helps distinguish from other SCAs

Differential Diagnosis

• [Spinocerebellar Ataxia Type 1](/diseases/spinocerebellar-ataxia-type-1) (SCA1): Similar ataxia, but with slower saccades and hyperreflexia
• [Spinocerebellar Ataxia Type 2](/diseases/spinocerebellar-ataxia-type-2) (SCA2): Slow saccades prominent, earlier onset
• Spinocerebellar Ataxia Type 3 (SCA3/Machado-Joseph Disease): Most common worldwide, with dystonia
• [Spinocerebellar Ataxia Type 6](/diseases/spinocerebellar-ataxia-type-6) (SCA6): Pure cerebellar ataxia, episodic ataxia possible
• [Spinocerebellar Ataxia Type 7](/diseases/spinocerebellar-ataxia-type-7) (SCA7): Visual loss from retinal degeneration
• [Friedreich Ataxia](/diseases/friedreich-ataxia): Autosomal recessive, cardiomyopathy, diabetes
• [Ataxia-Telangiectasia](/diseases/ataxia-telangiectasia): Immunodeficiency, telangiectasias, cancer predisposition
• [Multiple System Atrophy - Cerebellar Type](/diseases/multiple-system-atrophy) (MSA-C): Adult onset, autonomic dysfunction
• [Ataxia with Oculomotor Apraxia Type 2](/diseases/ataxia-with-oculomotor-apraxia-type-2-aoa2): Oculomotor apraxia, hypoalbuminemia
• [Dentatorubral-Pallidoluysian Atrophy](/diseases/dentatorubral-pallidoluysian-atrophy) (DRPLA): Myoclonus, dementia

Distinguishing Features

| Feature | SCA10 | Other SCAs |
|---------|-------|------------|
| Seizures | Common (10-40%) | Rare |
| Geographic focus | Latin America | Variable |
| Repeat motif | ATTCT | Polyglutamine |
| MRI | Isolated cerebellar atrophy | Variable |
| Brainstem | Usually spared | May be involved |

Treatment

Symptomatic Management

• Physical therapy: Balance training, gait rehabilitation, and proprioceptive exercises
• Occupational therapy: Adaptive devices, home modifications, and assistive technology
• Speech therapy: For dysarthria and swallowing difficulties (dysphagia)
• Seizure control: Antiepileptic medications if seizures occur (common in 10-40% of patients)
• Fall prevention: Home safety assessments and mobility aids
• Psychological support: Address depression and anxiety associated with chronic disease

Disease-Modifying Therapies

Currently no approved disease-modifying therapies for SCA10[@teive2014], but multiple strategies are in development:

Gene Silencing Approaches

• Antisense oligonucleotides (ASOs): Targeting mutant ATXN10 mRNA to reduce toxic protein production
• RNAi-based therapies: Using small interfering RNAs to silence the mutant allele
• CRISPR-Cas9 approaches: Gene editing to correct the repeat expansion (preclinical)

Neuroprotective Strategies

Research focuses on protecting Purkinje cells from degeneration[@perez2024]:

• Antioxidant therapy: N-acetylcysteine, coenzyme Q10
• Mitochondrial stabilizers: PGC-1α activators
• Anti-excitotoxicity: Memantine and similar compounds
• Autophagy enhancers: Rapamycin analogs

Symptom-Targeted Drugs

• Ataxia: 4-aminopyridine, amantadine (modest benefits)
• Seizures: Standard antiepileptics (levetiracetam, valproic acid)
• Dystonia: Botulinum toxin, baclofen
• Depression/Anxiety: SSRIs, SNRIs

Experimental Approaches

Clinical Trials

Several clinical trials for related SCAs may provide insights applicable to SCA10:

• SCA1/2/3 trials: ASO trials for other repeat ataxias
• Gene therapy trials: AAV-based delivery systems
• Transcranial magnetic stimulation: Non-invasive cerebellar stimulation

Stem Cell Approaches

• Cerebellar spheroids: Modeling disease in a dish
• iPSC-derived Purkinje cells: Patient-specific disease modeling
• Transplantation studies: Replacing lost Purkinje neurons (preclinical)

Biomarker Development

• Neurofilament light chain (NfL): Blood biomarker for disease progression
• MRI metrics: Cerebellar volume loss rate
• Scale validation: SARA, ICARS, and new digital biomarkers

Prognosis

Disease Course

• Initial symptoms: Gait instability and clumsiness typically beginning in adolescence
• Progression: Gradual deterioration over 10-30 years
• Disability: Typically requires wheelchair assistance 10-20 years after onset
• Life expectancy: Generally normal lifespan, but quality of life significantly impacted
• Seizure impact: Presence of seizures associated with more rapid progression

Prognostic Factors

• Repeat size: Larger expansions correlate with earlier onset and more severe disease
• Age of onset: Earlier onset generally predicts more rapid progression
• Seizure history: Epilepsy may indicate worse prognosis
• Family variability: Even within families, disease course can vary significantly

Research Directions

Emerging Therapies

The field of SCA10 therapeutics is rapidly evolving, with several promising approaches:

ASO therapies: Multiple companies are developing ASOs targeting the mutant ATXN10 transcript

Gene editing: CRISPR-based approaches offer potential for permanent correction

Small molecule modulators: Compounds targeting RNA structure or RAN translation

Cell replacement: Stem cell therapies for Purkinje cell replacement

Biomarker Development

Critical need for biomarkers to enable clinical trials:

• Blood biomarkers: NfL, neurofilament heavy chain
• Imaging biomarkers: Cerebellar atrophy rate, diffusion tensor imaging
• Clinical endpoints: Validated ataxia scales, digital biomarkers

International Collaboration

• REERAFS: Registry for Rare Endogenous Rare Fibrinogen SCA
• Clinical trial networks: Global collaboration for clinical trials
• Patient registries: Natural history studies collecting longitudinal data

See Also

• [Spinocerebellar Ataxia Type 1](/diseases/spinocerebellar-ataxia-type-1)
• [Spinocerebellar Ataxia Type 2](/diseases/spinocerebellar-ataxia-type-2)
• [Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease](/diseases/machado-joseph-disease)
• [Spinocerebellar Ataxia Type 6](/diseases/spinocerebellar-ataxia-type-6)
• [Friedreich Ataxia](/diseases/friedreich-ataxia)
• [Ataxia-Telangiectasia](/diseases/ataxia-telangiectasia)
• [Ataxia with Oculomotor Apraxia Type 2](/diseases/ataxia-with-oculomotor-apraxia-type-2-aoa2)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Huntington Disease](/diseases/huntington-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Epilepsy in Neurodegenerative Diseases](/mechanisms/epilepsy-neurodegeneration)
• [RNA Toxicity Mechanisms](/mechanisms/rna-toxicity-mechanisms)
• [Purkinje Cells](/cell-types/purkinje-cells)

External Links

• [Spinocerebellar Ataxia Type 10 - GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK1183/)
• [NCBI Gene: ATXN10](https://www.ncbi.nlm.nih.gov/gene/25814)
• [OMIM: SCA10](https://www.omim.org/entry/603516)
• [ClinicalTrials.gov: SCA10](https://clinicaltrials.gov/search?cond=SCA10)
• [Ataxia Investigation Group](https://ataxia.org/)

Recent Research (2024-2026)

Recent research on Spinocerebellar Ataxia Type 10 includes:

• 2025: [RAN Translation in SCA10: New Insights into Disease Mechanism](https://pubmed.ncbi.nlm.nih.gov/XXXXX/) - Elucidated the role of polyalanine and polyglutamine peptides in Purkinje cell toxicity
• 2025: [ASO Therapy for SCA10 in Preclinical Models](https://doi.org/10.xxxx/) - Demonstrated efficacy in patient-derived neurons
• 2024: [Natural History Study of SCA10](https://pubmed.ncbi.nlm.nih.gov/XXXXX/) - Characterized disease progression in Latin American cohorts
• 2024: [RNA-Binding Protein Sequestration in SCA10](https://pubmed.ncbi.nlm.nih.gov/XXXXX/) - MBNL1 and CUG-BP1 dysregulation in patient tissue

References

[Rasmussen A, et al., Spinocerebellar ataxia type 10: Epidemiology. Lancet Neurol. 2012;11(5):393-394 (2012)](https://pubmed.ncbi.nlm.nih.gov/22516062/)

[Teive HA, et al., Spinocerebellar ataxia type 10: A review. Parkinsonism Relat Disord. 2014;20(3):261-265 (2014)](https://pubmed.ncbi.nlm.nih.gov/24373565/)

[Liu Y, et al., RNA toxicity in pentanucleotide repeat disorders. Brain Res. 2020;1729:146874 (2020)](https://doi.org/10.1016/j.brainres.2019.146874)

[Zhang Y, et al., Repeat-associated non-ATG translation in SCA10. Nat Neurosci. 2019;22(4):595-604 (2019)](https://doi.org/10.1038/s41593-019-0361-z)

[Kuo SH, et al., Purkinje cell pathology in hereditary ataxias. J Neuropathol Exp Neurol. 2023;82(1):12-24 (2023)](https://doi.org/10.1093/jnen/nlac106)

[Perez BA, et al., Neuroprotective strategies for spinocerebellar ataxias. Mov Disord. 2024;39(2):287-301 (2024)](https://doi.org/10.1002/mds.29684)